Changes in protein stability have sometimes been associated with oncogenic activation. For example, truncations of the protein products of c-jun, c-fos, and c-mos occurred during transduction into retroviruses and resulted in both increased stability and increased transforming capacity compared to endogenous counterparts. Similarly, truncated versions of the transcriptional regulator c-Myb, found to be expressed in murine myeloid leukemias due to retroviral insertional mutagenesis, have been found to be more resistant to proteolysis than the normal protein (Bies and Wolff, Oncogene 14: [203][204][205][206][207][208][209][210][211][212] 1997).
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Carboxy-terminal (CT) truncations of the c-Myb protein involving 240-248 aa had been observed in MuLV-induced murine myeloid leukemias MML RI-4-11 and NFS-60 and a transformed myeloid cell line, VFLJ2. In all of these cases, truncation was caused by retroviral insertion into exon 9 and termination of translation in the 5′ retrovirus LTR. Interestingly the steady state levels of the truncated protein, as demonstrated by immune precipitation or by Western blot analysis, were much higher in RI-4-11 and NFS-60 cells when compared to the endogenous full length protein in M1 myeloblastic cells. This increase in steady state level was subsequently shown to be due in part to a change in turnover rate of truncated protein. When the protein which was missing 248 aa at the CT was expressed in M1 cells, it was approximately three times more stable than the full length endogenous c-Myb protein expressed in the same cells. Differences in expression, therefore, were due to changes in degradation rates that were in turn dependent upon protein structure and not just to the intrinsic proteolytic potentials of the leukemic cell lines.
Studies were subsequently carried out to determine the basic mechanism of proteolysis of the normal protein and to try to understand how the truncated form was escaping this breakdown. With the use of inhibitors of proteolytic pathways involving lysosomes, calpains and the 26S proteasome we were able to show that the 26S proteasome was responsible for breakdown of the protein in hematopoietic cells. In addition, we were able to show that c-Myb can be polyubiquitinated in vitro, suggesting that processing of c-Myb is through the common pathway involving ubiquitination and recognition of ubiquitinated protein by the proteasome (Bies and Wolff, Oncogene 14: 203-212, 1997). Since efficient ubiquitination of the full length, but not truncated protein was demonstrated, it is likely that inefficient ubiquitination of truncated protein leads to its escape from degradation.
Our recent studies have shown that CT truncation of 96 aa of c-Myb, a consequence of retrovirus integration in another of our myeloid leukemia cell lines, also results in stabilization although to a lesser extent than that observed for the RI-4-11 protein that is missing 248 aa (see Figure 1) .
In an attempt to localize areas of the CT portion of the protein that affect rates of degradation of the normal protein, we constructed a series of deletion mutants which were transiently expressed in COS 7 cells and analyzed in a pulse chase experiment. Two sets of deletion mutants were prepared. The Map depicting the normal c-Myb protein and proteins with truncations of 248 aa and 96 aa which are found in leukemias, RI-4-11 and 45-16, respectively. R1, R2, and R3 are tandem repeats that comprise the DNA binding domain; PEST 1, 2, 3 are putative PEST sequences identified by the PEST-FIND program; TA, transactivation domain; LZ, putative leucine zipper. first set consisted of increasingly larger deletions from the CT to beyond the putative leucine zipper region of c-Myb. The other set consisted of internal deletions. This analysis indicated that two areas may be involved in the proteolysis of cMyb, one in the very far CT end of c-Myb and one that overlaps the putative leucine zipper region. The fact that deletion of sequences in the leucine zipper region had a stabilizing effect on the protein suggests that perhaps protein-protein interaction through this area may be involved in the targeting of c-Myb for degradation by the proteasome. Mutation of the conserved PEST 3 sequence (see Figure 1 ) and a phosphorylation site, S528, shown to be important for transcriptional activation of some promoters, did not alter the turnover of the cMyb protein.
Additional experiments performed recently have demonstrated that phosphorylation is involved in c-Myb proteolysis. Treatment of M1 cells with okadaic acid, an inhibitor of ser/thr phosphatases, resulted in extremely rapid degradation of the endogenous full-length protein. Addition of an inhibitor of the 26S proteasome, ALLN, in the presence of okadaic acid resulted in stabilization of the protein. The stabilized protein had reduced electrophoretic mobility and appeared to be more highly phosphorylated than usual since there was a smear of higher molecular forms that could be reduced to a single band by in vitro treatment with alkaline phosphatase. Mutations of casein kinase II sites (S11,12) in the amino-terminal region of c-Myb or a MAPK site at S528 did not stabilize c-Myb in the presence of okadaic acid. Deletion of the entire CT to an extent that mimicked the truncations observed in leukemias, however, had a significant stabilizing effect. Although it is evident that c-Myb is highly phosphorylated at the time it is rapidly degraded, we cannot rule out the possibility that the phosphorylation of another protein is critical in this process.
Since c-Myb could be rapidly degraded in a situation where there was hyperphosphorylation in the cells, we wondered if it could be induced to rapidly degrade during differentiation of myeloid cells or at specific stages of the cell cycle. However, we found no difference in protein turnover at different phases of the cell cycle or at different times following treatment of M1 cells with IL-6 which induces these cells to differentiate to macrophages.
We conclude that there is a constitutive turnover of c-Myb in myeloid cells which is slowed down in the case of leukemia-specific truncated forms of the protein. The normal turnover mechanism involves protein phosphorylation and perhaps recognition through the putative leucine zipper region.
